Opposing responses of the rat pulmonary artery and vein to phenylephrine and other agents in vitro

Li-me Liao1,3, Li Zhou2*, Chen-ran Wang1, Jian-ying Hu1, Yao-jun Lu1 and Shaoqiang Huang1*

Abstract

Background: Different from current cognition, our study demonstrated that adrenergic receptors agonist phenylephrine significantly relaxed isolated pulmonary artery but constricted pulmonary veins. Through comparing differences in the effects of commonly used vasoactive drugs on pulmonary artery and veins, the study aimed to improve efficiency and accuracy of isolated pulmonary vascular experiments, and to provide experimental basis for clinical drug use.

Methods: The contractile responses of pulmonary arteries and veins from twelve-week-old Male Sprague-Dawley rats to phenylephrine, arginine vasopressin (AVP), U46619, endothelin-1, and potassium chloride (KCl) were recorded, as well as the relaxation in response to phenylephrine, AVP, acetylcholine. To further explore the mechanism, some vessels was also pre-incubated with adrenergic receptors antagonists propranolol, prazosin and nitric oxide synthesis inhibitor N[gamma]-nitro-L-arginine methyl ester (L-NAME) before addition of the experimental drugs.

Results: Phenylephrine constricted pulmonary veins directly, but constricted pulmonary artery only after incubation with propranolol or/and L-NAME. The pulmonary artery exhibited significant relaxation to AVP with or without L-NAME incubation. AVP more clearly constricted the veins after incubation with L-NAME. Changes in vascular tension also varied from pulmonary artery to veins for KCl stimulation. Different from phenomena presented in veins, acetylcholine did not relax pulmonary artery preconstricted by KCl, U46619, and endothelin-1.

Conclusions: According to the results, phenylephrine, KCl, AVP, and acetylcholine could be used to distinguish pulmonary arteries and pulmonary veins in vitro. This also suggested that the pulmonary arteries and pulmonary veins have great differences in physiology and drug reactivity.

Keywords: Arginine vasopressin, Phenylephrine, Potassium chloride, Pulmonary artery, Pulmonary vein, Vascular tension

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
of blood vessels, and in combination with acetylcholine to assess the integrity of the vascular endothelium.

The pulmonary artery is the resistance vessel of the right ventricular outflow tract. It is commonly used in vascular tension experiments investigating the pathogenesis and treatment of pulmonary hypertension. Presently, researchers generally believe that phenylephrine, as a vasoconstrictor drug, exerts a contractile effect in the pulmonary artery. However, previous in vitro studies have reported a significant variety of force generation in response to phenylephrine in pulmonary artery [1–6]. In 1999, a study by Lal et al. demonstrated that rat pulmonary veins under normal control and those in a chronic hypoxia model exhibited little contraction after stimulation by a phenylephrine concentration gradient, while the pulmonary artery exhibited concentration-dependent contraction [7]. In our experiments, however, an interesting phenomenon was observed. Stimulation of an isolated rat pulmonary artery using phenylephrine did not produce a contractile response, but significantly increased the vascular tone of the pulmonary vein. Based on inconsistent results reported in the literature, we questioned the differences in the contractile effects of phenylephrine on the pulmonary artery and veins, and the potential effector mechanisms.

Recent study have confirmed that phenylephrine can inhibit isolated myometrium contraction in mice by activating the β2 receptor [8]. In in vivo experiments, it has also been reported that endogenously released epinephrine attenuates pulmonary vasoconstriction and bronchoconstriction in systemic allergic reactions in Sprague-Dawley rats by activating β2-adrenergic receptors [9]. As such, does phenylephrine also inhibit pulmonary artery contraction and even produce a relaxation effect by activating β-receptors? Moreover, what role does nitric oxide (NO), the active component of endothelium-derived relaxing factor (EDRF), play? At the same time, our experiments revealed that phenylephrine clearly resulted in contraction of the pulmonary veins, suggesting that there is a significant difference in vascular reactivity to phenylephrine between the pulmonary arteries and veins. Furthermore, do other vasoactive drugs, which are commonly used in experiments, still have similar opposite phenomena on pulmonary arteries and veins.

Rodents are often used to study the pathophysiology of lung diseases. Based on the above questions, the present research aimed to explore the difference(s) in the vascular reactivity of healthy rat isolated pulmonary arteries and veins to phenylephrine, and to explore its mechanism of action. In addition, differences in the effect of arginine vasopressin (AVP), endothelin, U46619, and other common vasoactive drugs on the pulmonary artery and pulmonary veins were observed. Exploring these issues would be beneficial in distinguishing intralobar pulmonary arteries and veins, which could improve the efficiency and accuracy of isolated pulmonary vascular experiments and have more clear knowledge to pulmonary vessels, and to provide an experimental basis for clinical drug use.

Methods
Animal preparation

Approved by the Animal Ethics Committee of Shanghai Medical College of Fudan University [Approval number: 201907008Z], twelve-week-old Male Sprague-Dawley rats (343 ± 11 g), purchased from Shanghai Jiesijie Experimental Animal Co. LTD., were housed for 4 days in the animal facility and maintained on ad libitum standard rat chow and tap water in 12:12-h light-dark cycle. In the present experiment we total used 37 rats. The number of rats used in different experimental parts had been indicated in the corresponding legends. In order to reduce unnecessary sacrifices, datas from some rats were reused (N = 14 in Fig. 5). Rats were administered pentobarbital via intraperitoneal injection at 140 mg/kg for euthanasia. After breathing and heartbeat disappear, the chest was quickly opened, and the heart and lungs were removed and immersed in cool, oxygenated physiologic salt solution (PSS) with the following composition: (mmol) NaCl, 118.3 ; KCl,4.7 ; MgSO4,1.2 ; KH2PO4, 1.22; CaCl2, 2.5; NaHCO3, 25.0; calcium-ethylenediaminetetraacetic acid, 0.016, and glucose, 11.1 .

Isolation of pulmonary artery and veins

The superior and inferior vena cava were used as landmarks to confirm the location of the right atrium, and to search for the pulmonary artery at the hilum, upward from the right atrium. The pulmonary vein was searched upward from the left atrium. After fully trimming lung parenchyma that stuck to pulmonary vascular, the pulmonary vein segments with internal diameter ~ 200 μm and the pulmonary artery segments with internal diameter ~ 400 μm, all in 3 mm in length, were transected from the lung.

In vitro experiments

Segments of the pulmonary blood vessels were suspended in organ chambers filled with control solution (5 ml) maintained at 37 °C and bubbled with 95% oxygen and 5% carbon dioxide (pH 7.4) in a vascular tone measurement system (620 M, Danish Myo Technology, Denmark). Each blood vessels was equilibrated for 1 h at the mean optimal resting tension (5 mN). After equilibration, 60 mM potassium chloride (KCl) was added to fully activate the vascular ring and evaluate vascular...
activity. In the present experiments, the vascular endothelium was divided into nondisruptive endothelium and disrupted endothelium, the later was damaged by gently rubbing the intimal surface of the vessel using a pair of watchmaker’s forceps [10]. In the present experiment, the pulmonary vessels were randomly assigned to different treatment groups.

In contraction experiments, endothelin-1 (10 pM to 0.1 µM), phenylephrine (1 nM to 100 µM), or AVP (10 pM to 1 µM) were added in cumulative half-log₁₀ increments, allowing time for the response to plateau between additions. Contractions in response to each drug concentration are expressed as %KPSS maximum contraction within the blood vessels.

In experiments investigating relaxation of the pulmonary artery in response to phenylephrine or AVP, the pulmonary arteries were precontracted to 60–75% KPSS maximum using U46619 (a thromboxane A2 receptor agonist [300 to 800 nM]) [7, 10]. AVP and phenylephrine were added in cumulative half-log₁₀ increments allowing time (approximately 2 min) for the responses to plateau between additions. Control experiments were also performed to determine the effect of time on U46619-induced tone. In some parts of the study, the vascular ring was pre-incubated with receptor antagonists (5 × 10⁻⁶ M propranolol and 2 × 10⁻⁵ M prazosin) or inhibitors (2 × 10⁻⁴ M N[gamma]-nitro-L-arginine methyl ester [L-NAME]) for 30 min before addition of the experimental drug(s) [7, 11]. And in the present study all control group was added solvent distilled water or dimethyl sulfoxide the same as corresponding experiment group.

Vascular rings that did not respond to KCl were excluded from further experimentation. And blood vessels that disconnected from the pulmonary arteries or veins trunk before removing of the lung connective tissue around the target vessels would also not be used in the experiment, which aimed to ensure that the isolated blood vessel was the exact pulmonary artery or pulmonary vein.

Drugs
The drugs used in the experiments were all purchased from MedChemExpress: phenylephrine, acetylcholine, AVP, propranolol hydrochloride, prazosin hydrochloride, endothelin-1 and L-NAME (Calbiochem, San Diego, CA, USA). All powdered drugs were prepared using distilled water, except for propranolol and prazosin, which were dissolved in dimethyl sulfoxide. The concentrations are expressed as final molar concentration in the organ chambers.

Statistical analysis
All data are expressed as mean ± 1 standard error of the mean (SEM). Concentration-response curves were fitted using Prism version 8 software (GraphPad Inc, San Diego, Ca, USA) for each individual experiment. The differences between the groups at each concentration was analysed with one-way analysis of variance (ANOVA) and Bonferroni post hoc comparison (2-sided), or Student t-test, using SPSS version 22 (IBM Corporation, Armonk, NY, USA). In all experiments, N represented the number of animals from which blood vessels were obtained. In all cases, P < 0.05 was accepted as statistically significant.

Results
Contraction responses of the pulmonary artery and veins to phenylephrine
Phenylephrine itself did not constrict pulmonary artery. However, phenylephrine increased vascular tone in a concentration-dependent manner when the pulmonary arteries were pretreated with propranolol or L-NAME, or both, for 30 min. At 3 × 10⁻⁷ M of phenylephrine, the difference only existed between the L-NAME pretreatment group and the propranolol pretreatment group. At 10⁻⁶ M and 3 × 10⁻⁶ M of phenylephrine, pulmonary artery tension after L-NAME pretreatment was significantly greater than that in pulmonary arteries pretreated with propranolol, and combined L-NAME and propranolol. There was no difference between the propranolol pretreatment group and the combined propranolol and L-NAME pretreatment group at each phenylephrine concentration. With increases in phenylephrine concentration, vascular tension in the L-NAME pretreatment group first increased and then decreased, while it did not decrease in the other two groups. However, the maximum vascular tension stimulated with phenylephrine did not exhibit a significant difference among the three groups (propranolol, 14.5 ± 2.3%; L-NAME, 16.6 ± 1.9%; combined, 17.2 ± 3.0%; p = 0.721) (Fig. 1).

There was no difference in the contractile effect of phenylephrine on the pulmonary veins in each group with or without pre-incubation with propranolol or/and L-NAME (control, 67.3 ± 1.8%; propranolol: 69.9 ± 1.7%; L-NAME, 67.1 ± 8.2%; combined [i.e., L-NAME and propranolol], 62.3 ± 4.5%; p = 0.455) (Fig. 1).

Relaxation response of pulmonary arteries to phenylephrine
After pretreatment with U46619 (sham group), the pulmonary artery tension did not decrease significantly. Phenylephrine reduced pulmonary artery tension in a concentration-dependent manner at drug
concentrations $> 10^{-6}$ M, and was statistically significant at $10^{-4}$ M. After 30 min of pre-incubation with prazosin, an $\alpha_1$ adrenergic blocker, the relaxation effect of phenylephrine was more distinct; comparing with the sham group, statistically significant differences were found at $\geq 10^{-6}$ M, and at $10^{-4}$ M compared with the control group (Fig. 2A).

Compared with the group incubated only with prazosin, the group preincubated with prazosin and L-NAME, the relaxation effect of phenylephrine was weakened at all concentrations, but was still significantly different at $10^{-4}$ M. After 30 min-preincubation with prazosin and propranolol, significant relaxation effect of phenylephrine was produced only at $10^{-6}$ M. Compared with the group incubated only with prazosin, the group preincubated with prazosin and propranolol almost completely reversed the relaxation effect when the phenylephrine concentration was $> 10^{-6}$ M (Fig. 2B).
Constriction response of the pulmonary artery and veins to AVP
Compared with pulmonary veins that were not incubated with L-NAME for 30 min, the pulmonary veins incubated with L-NAME exhibited an increased sensitivity to gradient concentrations of AVP, and vascular tone continued to increase with increasing AVP concentration, and did not decline or decay. Pulmonary artery did not response to AVP (Fig. 3).

Relaxation response of the pulmonary artery to AVP
Comparing with sham group, pulmonary artery tension was significant lower at AVP concentrations $\geq 3 \times 10^{-10}$ M in the group without L-NAME incubation while only significant lower at $10^{-8}$ to $10^{-7}$ M in group with L-NAME incubation. Regardless of whether pre-incubated with L-NAME, after pulmonary artery contraction induced by U46619, vascular tension first decreased and then increased with increases in AVP concentration. Maximal relaxation occurred at an AVP concentration of $3 \times 10^{-8}$ M in both AVP treatment groups. Compared with the pulmonary artery incubated with L-NAME for 30 min, the pulmonary artery without L-NAME incubation demonstrated more pronounced relaxation with increases in AVP concentration. Furthermore, vascular tension in the sham group did not decrease significantly during the experiment (Fig. 4).

Response of pulmonary artery and veins to KCl and acetylcholine
After adding KCl, the vascular tension increased rapidly to a maximum value and then decreased slowly in pulmonary artery with an intact endothelium, endothelium-injured pulmonary artery, and pulmonary artery pre-incubated with L-NAME. Regardless of whether the vascular endothelium of the pulmonary artery was damaged, acetylcholine could not relax the arteries. After adding KCl, the vascular tension first increased rapidly and then increased slowly and finally stabilized at the maximum tension value in pulmonary veins with intact endothelium, damaged endothelium, and pulmonary veins incubated with L-NAME. Acetylcholine clearly relaxed the pulmonary vein with intact endothelium, and slightly relaxed the pulmonary vein with damaged endothelium. Response of pulmonary artery and pulmonary veins to KCl were independent of L-NAME incubation (Fig. 5).
Response of pulmonary artery and pulmonary veins to acetylcholine

Pulmonary artery pre-constricted with U46619 and endothelin-1 had no relaxation response to acetylcholine; whereas pulmonary veins pre-contracted with U46619 and endothelin-1 exhibited significant relaxation response to acetylcholine (Fig. 6).

Discussion

The main findings of the in vitro study in healthy rats were as follows. First, phenylephrine exerted a relaxing effect on the pulmonary artery through activation β-receptor and increasing NO synthesis, but demonstrated expected constriction effect on pulmonary veins. Second, AVP relaxed pulmonary arteries significantly with or without L-NAME incubation. After incubation with L-NAME, AVP constricted the pulmonary veins more strongly. Third, the differences between pulmonary arteries and pulmonary veins was also reflected in the response to KCl and acetylcholine.

A recent study demonstrated that phenylephrine inhibits myometrium contraction in mice, with an IC_{50} of approximately 10^{-6} M through activation of the β_2-receptor in a concentration-dependent manner [8]. Our experimental findings were similar to this conclusion. Phenylephrine itself did not constrict pulmonary arteries,
but produced significant constriction effect at concentration $\geq 10^{-6}$ M after pretreatment with propranolol. Furthermore, after incubation with $\alpha$-blockers, phenylephrine significantly relaxed the pulmonary artery at concentrations $\geq 10^{-6}$ M in a concentration-dependent manner, while the relaxation effect of phenylephrine decreased remarkably after further inhibiting $\beta$-receptor. At the same time, the rising speed of the constriction curve with L-NAME pretreatment slowed down and then declined at drug concentrations $> 10^{-6}$ M, which was also due to $\beta$-receptor activation. Therefore, constriction curves of the pulmonary arteries pretreated with both propranolol and L-NAME did not exhibit this phenomenon in the same phenylephrine concentration range. This suggested that phenylephrine was not a pure $\alpha$-receptor agonist as known currently because it also exerted a significant $\beta$-receptor agonist effect at concentrations $> 10^{-6}$ M.

We also found that after inhibiting NO synthetase phenylephrine concentration-dependently constricted the pulmonary artery even at low concentration. Additionally, in the relaxation experiment, phenylephrine still significantly relaxed the pulmonary artery at $10^{-6}$ M after pretreatment with prazosin and propranolol, which was due to NO synthesis. We also noticed that at concentration $> 10^{-6}$ M the constriction effect of phenylephrine decayed on pulmonary artery pretreated with L-NAME. And the relaxation effect of phenylephrine caused by NO synthesis was only significant at $10^{-6}$ M and reduced at concentrations $> 10^{-6}$ M. This suggested that the relaxation effect of phenylephrine caused by NO synthesis mainly occurred at concentrations $\leq 10^{-6}$ M.

Collectively, there were three effects on pulmonary artery induced by phenylephrine: the constriction effect following $\alpha$-receptor activation; the relaxation effect after activation of the $\beta$-receptor; and the relaxation effect of NO synthesis. Ultimately, the effect of phenylephrine on pulmonary artery is relaxation. One supported study demonstrated that during exercise, when the levels of sympathetic active substances increase to activate lots of $\alpha$ and $\beta$ receptors, as well as the synthesis of NO in large quantities, the balance is conducive to net mild pulmonary vasodilation [12]. Clinical studies also demonstrate that norepinephrine infusion increase mean arterial pressure while not affecting or decreasing pulmonary artery pressure [13, 14]. In summary, the relaxation effect of phenylephrine was mainly due to the production of NO at concentrations $\leq 10^{-6}$ M while activating

![Fig. 6 Responses of the pulmonary arteries and veins to acetylcholine. Isometric tension recording of the effect of acetylcholine ($10^{-9}$ to $10^{-3}$ M) on pulmonary artery and vein segments pretreated with U46619 or endothelin-1 rats (N = 5). The number of rats is the number of repetitions of each group.](image-url)
β-receptors at concentrations > 10^{-6} M. That was also the reasons why the maximum pulmonary artery constricttion effect induced by phenylephrine after pretreatment with propranolol and L-NAME was not significantly stronger than that of after propranolol or L-NAME pre-treatment alone.

Our study also suggested that after pre-incubated with L-NAME and propranolol, although the constricttion effect of pulmonary arteries stimulated by phenylephrine was significantly increased, it was still weak (17.2 ± 3.0 %). We speculated that endothelium dependent hyperpolarizing factor (EDHF), one component of endothelium-dependent relaxation, may also play an vital role in the tension of pulmonary arteries. The vasodilation mechanism of EDHF can be directly caused by calcium-activated potassium channels, or conducted by CX40 protein in gap junction after hyperpolarization of endothelial cells [15]. There are three subtypes of calcium-activated potassium channels related to the action of EDHF, namely large conductance calcium-activated potassium channel (BKCa), medium conductance calcium-activated potassium channel (IKCa) and small conductance calcium-activated potassium channel (SKCa). Garland et al. [16] found that BKCa was located on the smooth muscle membrane and was the binding site of EDHF; IKCa and SKCa only appear in endothelium cells [17]. Due to this distribution of calcium-activated potassium channels, one previous study have shown that the vasodilation of EDHF was attenuated by NO synthase inhibition in the pulmonary artery of rats [18], while another studies have reported that the vasodilation effect of EDHF continues significantly in the presence of the combination of L-NAME and the cyclooxygenase inhibitor indomethacin [19]. One recent study supported that after inhibition BKCa, phenylephrine-induced contraction of pulmonary artery rings enhanced about 25% [20].

However, phenylephrine concentration-dependently constricted pulmonary veins, and there was no difference in the contractile effect of phenylephrine in each group with or without pre-incubation with propranolol or/ and L-NAME. We concluded that for pulmonary veins, phenylephrine demonstrated only a contractile effect through activating α1 receptor with little NO production or β-adrenergic receptor activation effect.

We speculated that the difference between the pulmonary arteries and veins was due to different distribution of β-receptors and production of NO. Compared to pulmonary vein, pulmonary artery had a denser distribution of β-receptors and a greater amount of NO production. An earlier study also supported this conclusion, suggesting that most of the effects of beta blockade and EDRF suppression occur mainly in pulmonary artery and extra-alveolar blood vessels [12]. We believed that the relaxation response of pulmonary artery to the adrenergic receptor agonist was a self-protection mechanism of the healthy organism to avoid pulmonary arterial hypertension while increasing mean arterial pressure.

While investigating the different responses of the pulmonary artery and veins to AVP, we found that AVP significantly relaxed pulmonary artery pre-constricted with U46619, and achieved the maximum relaxation effect at a concentration of 3 × 10^{-8} M. Other studies involving rats also demonstrated that AVP reduced the pulmonary vascular resistance index in vivo [21] and in vitro (6). Studies also showed that vasopressin-induced pulmonary artery relaxation was caused by the production of NO [22, 23] mediated by V1-receptor in the intact vascular endothelium [23]. However, our experiment also revealed that AVP still significantly relaxed pulmonary artery after pre-incubation with the NO synthase inhibitor L-NAME, which although was obviously weaker than that in untreated group. Moreover AVP still hardly constricted L-NAME-pretreated pulmonary artery. Therefore, we believed that AVP relaxed pulmonary artery not only through NO synthesis pathway(s). A previous study reported that AVP reversed approximately 65% of U-46,619-induced pulmonary vascular constriction, mainly caused by the activation of V1 receptors; AVP also produced approximately 8% pulmonary artery relaxation by activating V2 receptors [24]. We speculate that this non-NO synthesis pathway was mediated by V2 receptor. AVP constricted pulmonary veins more significantly after L-NAME pre-incubation, which indicated AVP could induce NO production in the pulmonary veins.

Our study also found that differences in changes in vascular tension stimulated by KCl between pulmonary arteries and veins was also one of the methods to distinguish the two in vitro. It was not related to the integrity of the vascular endothelium or the amount of NO production. We speculated that this was probably due to the different arrangement of smooth muscle layers in pulmonary artery and veins and the different characteristics of ion channels in smooth muscle. BKCa is the predominant potassium channel of vascular smooth muscle, and its activation negatively regulates vascular tone. The cell membrane depolarization increases vascular tension through increasing intracellular calcium concentration; and the increasing Ca^{2+} activates calcium-activated potassium channels results potassium outflow, which leads to cell membrane potential repolarization and superpolarization; and following voltage-dependent Ca^{2+} influx decreases or stops, the tension of vascular smooth muscle gradually decreases [25-27]. In KCl stimulation experiment, the phenomenon that pulmonary artery tension gradually decreased after rapidly reaching maximum value was probably caused by BKCa.
Another supporting study also showed that EDHF-mediated relaxation was sensitive to 60 mM K(+) depolarizing solution in pulmonary arterial rings [18]. The calcium-activated potassium channels seen in smooth muscle cells also change from BKca to IKca predominance in PAH [28]. One literature also suggested that the relaxation of EDHF is influenced by multiple factors, including vascular distribution and caliber, pre-existing tone [29]. This suggested that the BKCa activity and quantity in the pulmonary vein smooth muscle may be significantly different from that of the pulmonary artery, which led to different constriction curves in potassium stimulation.

We also found that the endothelial function of pulmonary veins could be determined by the relaxation effect of acetylcholine. However, pulmonary arteries could not be relaxed by acetylcholine regardless of whether the endothelial of vessels were damaged. Pulmonary artery pre-constricted by U46619 and endothelin-1 still cannot be relaxed by acetylcholine while acetylcholine clearly relaxed such pre-constricted pulmonary veins. Although previous studies and ours have confirmed that AVP can significantly relax the pulmonary artery, but our experiments also revealed that this relaxation effect also occurred after the inhibition of NO synthase. Therefore, the relaxation effects of AVP do not appear to be a good predictor of endothelial function in pulmonary arteries.

Earlier in vitro study showed that phenylephrine could not cause the constriction of pulmonary veins in either chronic hypoxic or healthy rats, but could concentration-dependently constricted pulmonary artery; moreover, acetylcholine clearly relaxed U46619-precontracted pulmonary artery, but hardly relaxed pulmonary vein [7]. These results contradicted those of ours. The methods of free pulmonary artery and veins may further support the reliability of our study. We adopted a method of gradually approaching the target blood vessels from the outside to the inside. And the target blood vessel was always connected to the pulmonary vascular trunk during separation lung tissue to ensure the accuracy of the pulmonary arteries or pulmonary veins.

The tracheal tissues at all levels are closely intertwined with the pulmonary artery and pulmonary veins to maintain high-efficiency gas exchange. There are also bronchial circulation vessels with a nutrient function that belong to the systemic circulatory system. The further these tissues are from the hilum of the lung, the more difficult it is to distinguish them, especially after separation from the origin of the lumen tissue. Our study demonstrated that pulmonary artery and pulmonary veins could be distinguished by different responses to common drugs (i.e., KCl, phenylephrine, and acetylcholine), which improves the efficiency and accuracy of relevant in vitro experiments.

Nevertheless, there were still some limitations in the present study. We did not explore whether phenylephrine also exerts such different effects in pulmonary vascular with diseases. We did not further explore which subtype of beta receptor was activated by phenylephrine. Differences in the distribution of adrenergic receptors and the expression of NO synthase between the pulmonary artery and veins were not explored at the molecular level. Some studies have shown that phenylephrine significantly constricts the pulmonary arteriess of humans, dogs, pigs, and cattle [10, 23, 30, 31]; therefore, we speculate that the effect of phenylephrine on the pulmonary vascular may have significant species differences.

Conclusions
Our study demonstrated that phenylephrine significantly relaxed the pulmonary artery through the activation of β-adrenoreceptors and inducing NO production, but clearly constricted the pulmonary veins. We believe that AVP relaxed the pulmonary artery by producing NO, as well as non-NO synthesis pathways. When exposure to KCl, pulmonary artery tension gradually decreased after rapidly reaching maximum value, while pulmonary vein rapidly reached the maximum tension and stabilized at the maximum value. Different from the phenomenon presented in veins, acetylcholine did not relax pulmonary artery preconstricted by KCl, U46619, and endothelin-1. Obtaining human pulmonary vessels is difficult due to issues such as lack of access and ethics. Therefore, it is very popular to use rodents to study the occurrence and development of lung diseases. In vitro, the intralobar branches of pulmonary artery and pulmonary vein are easily confused due to similar small lumens, adjacent locations. According to our results, commonly used vasoactive drugs could quickly and effectively distinguish pulmonary arteries and pulmonary veins, which improves the accuracy and effectiveness of the relative experiment.

Abbreviations
ACh: Acetylcholine; NO: Nitric oxide; EDRF: Endothelium-derived relaxing factor; AVP: Arginine vasopressin; KCl: Potassium chloride; L-NAME: N(γ-gamma)-nitro-L-arginine methyl ester; EDHF: Endothelium-derived hyperpolarizing factor.

Acknowledgements
Thanks for Department of Physiology and Pathophysiology, School of Basic Medicine Science, Fudan University for providing laboratory. Thanks to the researchers of this laboratory for their guidance on experimental technology.

Authors’ contributions
LL and SH conceived and designed the study. LL, CW and LZ performed the experiment and collected data. JH and YL analyzed and interpreted the data. LL wrote the draft, LZ and SH revised it. All authors read and approved the final manuscript.
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials
Data are available from the authors upon reasonable request.

Declarations

Ethics approval and consent to participate
All animal experiments were performed in accordance with the recommendations of the Laboratory Animal Science (Qin C, Wei H. Laboratory Animal Science [M]. Beijing: People's Medical Publishing House, 2015). All animal manipulations were executed by trained researchers, certified with a Laboratory Animal Sciences course according to the Federation of European Laboratory Animal Science Association.

Consent for publication
Not applicable.

Competing interests
The authors have no competing interests to declare.

Author details
1Department of Anaesthesia, Obstetrics and Gynecology Hospital, Fudan University, 128 Shenyang road, Shanghai 200090, China. 2Department of Physiology and Pathophysiology, School of Basic Medicine Science, Fudan University, 130 Dongan Road, Shanghai 200032, China. 3Department of Anesthesiology and Perioperative Medicine, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 91 Jinsi Road, Guangzhou 510623, China.

Received: 1 July 2020   Accepted: 27 May 2021
Published online: 05 June 2021

References
1. Sheridan BC, McIntyre RJ, Meldrum DR, Fullerton DA. L-arginine attenuates endothelial dysfunction in endotoxin-induced lung injury. Surgery. 1999;125(1):33–40.
2. McIntyre RJ, Sheridan B, Agnaflo J, Fullerton DA. Endotoxin differentially impairs cyclic guanosine monophosphate-mediated relaxation in the pulmonary and systemic circulations. Crit Care Med. 1997;25(2):318–23.
3. Karpinska O, Baranowska-Kuczk M, Kloza M, Ambroz EE, Kozlowski T, Kasacka I, Malinowska B, Kozlowska H. Activation of CB1 receptors by 2-arachidonoylglycerol attenuates vasoconstriction induced by U46619 and angiotensin II in human and rat pulmonary arteries. Am J Physiol Regul Integr Comp Physiol. 2017;312(6):R883–93.
4. Abis M, Eid BG, Ashston N, Hart G, Gurney AM. Simvastatin causes pulmonary artery relaxation by blocking smooth muscle ROCK and calcium channels: evidence for an endothelium-independent mechanism. PLoS ONE. 2019;14(8):e220473.
5. Lopez-Valverde V, Andersen CU, Laursen BE, Mulvany MJ, Simonsen U. Gilbenclamide reveals role for endothelin in hypoxia-induced vasoconstriction in rat intrapulmonary arteries. J Cardiovasc Pharmacol. 2005;46(4):422–9.
6. Menendez C, Martinez-Caro L, Moreno L, Nin N, Moral-Sanz J, Morales D, Cogolludo A, Esteban A, Lorente JA, Perez-Vizcaino F. Pulmonary vascular dysfunction induced by high tidal volume mechanical ventilation. Crit Care Med. 2013;41(8):e149–55.
7. Lal H, Williams RJ, Woodward B. Chronic hypoxia differentially alters the responses of pulmonary arteries and veins to endothelin-1 and other agents. Eur J Pharmacol. 1999;371(1):11–21.
8. Chen X, Meroueh M, Mazur G, Rouse E, Gundal KS, Stamatkin CW, Obukhov AG. Phenytoinephine, a common cold remedy active ingredi- ent, suppresses uterine contractions through CAM signalling. Sci Rep. 2018;8(1):11666.
9. Zhang W, Shibamoto T, Kuda Y, Ohmukai C, Kurata Y. Pulmonary vasoconstrictive and bronchoconstrictive responses to anaphylaxis are weakened via beta2-adrenoceptor activation by endogenous epinephrine in anesthetized rats. Anesthesiology. 2011;114(3):614–23.
10. Currigan DA, Hughes RJ, Wright CE, Angus JA, Soeding PF. Vasoconstrictor Responses to Vasopressor Agents in Human Pulmonary and Radial Arteries: An In Vitro Study. Anesthesiology. 2014;121(5):930–936.
11. Sohn JT, Ding X, McCune DF, Perez DM, Murray PA. Fentanyl attenuates alpha1B-adrenoceptor-mediated pulmonary artery constriction. Anesthesia. 2005;103(3):327–34.
12. Kane DW, Tesauro T, Kozumi T, Gupta R, Newman JH. Exercise-induced pulmonary vasoconstriction after combined blockade of nitric oxide synthase and beta adrenergic receptors. J Clin Invest. 1994;93(2):677–83.
13. Trepape L, Voci P, Cogliati AA, Parotti E, Papalia U, Menichetti A. Successful weaning from cardiopulmonary bypass with central venous prostaglandin E1 and left atrial norpinephrine infusion in patients with acute pulmonary hypertension. Crit Care Med. 1999;27(10):2180–3.
14. Kwak YL, Lee CS, Park YH, Hong TW. The effect of phenylephrine and norpinephrine in patients with chronic pulmonary hypertension. Anesth. 2002;57(1):9–14.
15. Mather S, Dora KA, Sadow SL, Winter P, Garland CJ. Rapid endothelial cell-selective loading of connexin 40 antibody blocks endothelium-derived hyperpolarizing factor dilation in rat small mesenteric arteries. Circ Res. 2005;97(4):399–407.
16. Garland CJ, Hiley CR, Dora KA. EDHF: spreading the influence of the endothelium. Br J Pharmacol. 2011;164(3):839–52.
17. Busse R, Edwards G, Feletou M, Fleming I, Vanhoutte PM, Weston AH. EDHF: bringing the concepts together. Trends Pharmacol Sci. 2002;23(8):374–80.
18. Addison MP, Singh TU, Parida S, Choudhury S, Kasa JK, Sukumaran SV, Darzi SA, Kandasamy K, Singh V, Kumar D, et al. NO synthase inhibition attenuates EDHF-mediated relaxation induced by TRPV4 channel agonist GSK1016790A in the rat pulmonary artery: role of beta2A. Pharmacol Rep. 2016;68(3).
19. Uttam VSS, Subhasheer ST, E P , Ramasamy NRC, Kannan T, Vishakha K, Kumar S. MS. TRPV4 channel activation leads to endothelium-dependent relaxation mediated by nitric oxide and endothelium-derived hyperpolarizing factor in rat pulmonary artery. Pharmacol Res. 2013;78.
20. Melnyk MI, Ivanova IV, Dyon DY, Putsulskyi YI, Hurnmach YV, Platonov M, Al KL, Ritter U, Solovev AI, Zholos AV. C60 fullerenes selectively inhibit BKCa but not Kv channels in pulmonary artery smooth muscle cells. Nanomedicine UK. 2019;19:1–11.
21. Sugawara Y, Mizuno Y, Oku S, Goto T. Effects of vasopressin during a pulmonary hypertensive crisis induced by acute hypoxia in a rat model of pulmonary hypertension. Br J Anaesth. 2019;122(4):437–47.
22. Russ RD, Walker BR. Role of nitric oxide in vasopressinergic pulmonary vasoconstriction. Am J Physiol. 1992;262(3 Pt 2):H1473–4.
23. Evora PR, Pearson PJ, Schaff HV. Arginine vasopressin induces endothelium-dependent vasoconstriction of the pulmonary artery: VI receptor-mediated production of nitric oxide. Chest. 1993;103(4):1241–5.
24. Russ RD, Resta TC, Walker BR. Pulmonary vasodilatory response to neurohypophyseal peptides in the rat. J Appl Physiol (1985). 1992;73(2):473–8.
25. Yang Y, Murphy TV, Ella SR, Grayson TH, Haddock R, Hwang YT, Braun AP , Peichun G, Korthuis RJ, Davis MJ, et al. Heterogeneity in function of small artery smooth muscle BKCa channels. Physiol Rep. 2019;7(Pt 12):e14734.
26. He-Yun W, Xia-Shi L, Hai-Xia L, Yong-Mei C. Progress in the studies of alpha1B-adrenoceptor-mediated pulmonary artery contraction. Anesthesiology. 2014;121(5):930–936.
27. Brenner R, Perez GJ, Bonew AD, Eckman DM, Kosek JC, Weller SW, Patterson AJ, Nelson MT, Aldrich RW. Vasoregulation by the beta1 subunit of the calcium-activated potassium channel. Nature. 2000;407(6806):870–6.
28. Hayabuchi Y. The action of smooth muscle cell potassium channels in the pathology of pulmonary arterial hypertension. Pediatr Cardiol. 2017;38(1):1–14.

29. Loredana H, Lăcrămioara S, Cristina O, Simona T, Veronica L. The importance of EDHF in endothelium-dependent relaxation increases distally in mesenteric arteries depending upon the contracting agent. Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi. 2011;115(1).

30. Mirbahar KB, Eyre P. Autonomic and autacoid activity in antigen-sensitized and control ovine pulmonary vein and artery. J Vet Pharmacol Ther. 1982;5(2):137–44.

31. Gold ME, Wood KS, Byrns RE, Fukuto J, Ignarro LJ. NG-methyl-L-arginine causes endothelium-dependent contraction and inhibition of cyclic GMP formation in artery and vein. Proc Natl Acad Sci U S A. 1990;87(12):4430–4.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.